Influenza A virus H1N1 vaccine - Medicago

Drug Profile

Influenza A virus H1N1 vaccine - Medicago

Alternative Names: H1N1 VLP influenza vaccine - Medicago; Influenza A (H1N1) swine flu vaccine - Medicago; Influenza A H1N1 virus-like particle (VLP) vaccine - Medicago; Pandemic H1N1 virus vaccine - Medicago

Latest Information Update: 13 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Medicago
  • Class Influenza A virus H1N1 vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza A virus H1N1 subtype

Most Recent Events

  • 03 Mar 2017 Phase-II development is ongoing in USA and Canada
  • 18 Sep 2013 Medicago has been acquired by Mitsubishi Tanabe Pharma Corporation
  • 11 Dec 2012 Medicago receives grant from National Research Council of Canada for Influenza VLP vaccine candidate development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top